| Ytd | -19.98% | |
| 1y | 97.04% |
| Open | 31.88 | Prev Close | 32.36 | Low | 31.35 | High | 32.22 | Mkt Cap | 126.53M |
| Vol | 94.15K | Avg Vol | 74.03K | EPS | -0.75 | P/E | N/A | Forward P/E | -42.03 |
| Beta | 0.63 | Short Ratio | 1.50 | Inst. Own | 14.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 33.26 | 200-d Avg | 34.32 | 1yr Est | 35.00 |
VTVT News
HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analy
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to
HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, an
Top Wall Street analysts changed their outlook on top names. See all changes, including upgrades and
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the pric
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therape
vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet e
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stoc
HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stoc
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vT
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and in
Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts
Top Wall Street analysts changed their outlook on top names, including WLTH, FPI, CAG, VIV, and GIS.
Top Wall Street analysts changed outlook on certain stocks. See analyst ratings and advice on Rush S
Evercore ISI Group analyst Michael DiFiore initiates coverage on vTv Therapeutics (NASDAQ:VTVT) w
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.58) per share which beat the analyst
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to
I think VTVT is a largely underfollowed T1D catalyst story, with Phase 3 CATT1 cadisegliatin topline
vTv Therapeutics Inc. (NASDAQ: VTVT - Get Free Report) saw a large growth in short interest during t
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the developm
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclus
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the pric
Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy r
TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy ratin
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced a Phase
BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analy
HC Wainwright & Co. analyst Emily Bodnar reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analy
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clini